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1. Introduction 
1.1. Definition, epidemiology and classification of heart failure 
Heart failure (HF) can be defined as an abnormality of cardiac structure or function leading to failure 
of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing 
tissues. HF is defined, clinically, as a syndrome in which patients have typical symptoms (e.g. 
breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, 
pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or 
function. HF is the most common disease in the human population, approximately 0.5–2% of the adult 
population in developed countries has HF, with the prevalence rising to ≥10% among persons 70 years 
of age or older. In Europe, nearly 10 million people suffer from HF with an incidence of about 1– 
5/1000. Once hospitalized for HF, the mortality rates at 30 days, 1 year, and 5 years were as high as 
10%, 22%, and 50%, overrating the mortality rates of cancer. 
Based on the recommendation of the European Society of Cardiology (ESC), the main 
terminology used to describe HF is historical and is based on measurement of LV ejection fraction 
(EF). When the signs and symptoms of decompensation are associated with an EF >50%,  the 
diagnosis of HF with preserved EF (HFpEF) is satisfied. The diagnosis of HF with reduced EF is 
established, when the characteristics signs are associated with an EF <50%. 
Patients with an EF in the range 40 – 50% therefore represent a “grey area”, and most probably have 
primarily mild systolic dysfunction. This category is termed as HF with moderately reduced EF 
(HFmREF). 
 
1.2. Pathogenesis of heart failure 
HF is a complex, progressive clinical-pathological entity which is initiated by various etiological 
factors (ischaemic and non-ischaemic triggers) given rise to compensatory mechanisms occurring in 
the surviving myocytes and extracellular matrix. Neurohumoral activation (renin – angiotensin – 
aldosterone system, sympathetic nervous system and natriuretic factors) may counterbalance the 
decreased cardiac performance as short-time effects, but leading to pathological remodeling of the left 
ventricle (LV) with dilatation and further impaired contractility. Two mechanisms are thought to 
account for this progression. The first is occurrence of further events leading to additional myocyte 
death (e.g. recurrent myocardial infarction). The other is the systemic responses induced by the decline 
in systolic function, particularly due to neurohumoral activation by triggering pathological signaling 
pathways resulting in further cardiomyocyte necrosis, apoptosis and extracellular matrix fibrosis. 
 
1.3. Acute heart failure 
Acute heart failure (AHF) relates to the rapid decline in cardiac pump function requiring urgent 
medical care. AHF is also associated with high mortality rates: the estimated risk of death was 
reported around 3-4% in the hospital and approximately 10% after discharge within 60-90 days. AHF 
may arise as a de novo entity in a previously asymptomatic patient, as an acute exacerbation of 
previously diagnosed chronic HF or as a terminal stage of chronic HF. Briefly, the pathophysiology of 
AHF relies on a complex interaction between the weakened cardiac performance and increased 
systemic vascular resistance (SVR). A novel paradigm suggests that episodes of AHF can be classified 
as either an acute vascular or cardiac failure. Decline in the cardiac performance by diverse 
pathological processes (e.g. myocardial ischaemia, arrhythmia) results in a forward and backward 
failure, manifesting as low peripheral perfusion with renal impairment and fluid accumulation with 
severe pulmonary congestion. The vascular pathway is related to the increased SVR and arterial 
stiffness leading to elevations in the LV end-diastolic pressure (LVEDP). Hence, increased LV filling 
pressure contributes to pulmonary congestion with concomitant signs of AHF. Although one or 
another pathway dominates in certain clinical cases, the combination of the above pathologic pathways 
results in the initiation of AHF by promoting a vicious circle. 
 
1.4. Pharmacological treatment of AHF 
Current pharmacological therapies should respect the distinct clinical and pathophysiological entities 
of the AHF syndromes. Accordingly, in those patients with hypotension (RR <90 mmHg), 
hypoperfusion or shock, intravenous inotropic support should be considered to maintain the peripheral 
perfusion via increasing the cardiac output (CO) and the blood pressure (BP), while intravenous 
diuretics and vasodilators are recommended in patients with pulmonary and/or systemic venous 
congestion, as well as with signs of elevated filling pressures and vascular volume redistribution (RR 
>90 mmHg). 
Majority of the positive inotropic agents were shown to evoke beneficial hemodynamic effects 
but failed to improve the prognoses of HF, indeed the long-term morbidity and mortality rates were 
impaired after those inotropic intervention. Positive inotropic agents may improve the contractility of 
the myocardium via three different mechanism of action: 
1.) calcium (Ca2+) mobilizers acting by increasing the amplitude of the intracellular Ca2+ transient via 
interfering with the adrenergic signaling pathways, 
 
2.) modulation of the Ca2+  homeostasis of the sarcoplasmic reticle can augment Ca2+ release from the 
SR during systole and Ca2+ uptake during diastole, 
 
3.) sarcomere targeted agents activate directly the myofilaments. 
 
1.5. Mechanism of action and clinical implications for traditional inotropic agents 
Myocardial contractility depends partially on the intracellular Ca2+ concentration ([Ca2+]). Traditional 
positive inotropic agents load the cardiomyocytes with Ca2+ to improve cardiac contractility, termed 
thereby as Ca2+ mobilizers. β-adrenergic agonists are the most frequently used drugs for the treatment 
of AHF Dobutamine and adrenalin, acting as β-adrenergic agonists increase the intracellular Ca2+ level 
via activating this signaling pathway leading to protein kinase A (PKA) activation. 
Phosphodiestherase III (PDE III) inhibitors (e.g. milrinone, enoximone) enhance the contractility in 
cardiac myocytes and relaxation in the vascular smooth muscle cells by reducing the rate of cyclic 
adenosine monophosphate (cAMP) break-down. Despite of the increased myocardial contractility, this 
inotropic intervention can be complicated by deleterious side effects limiting its applicability in long- 
term therapies for patients with  AHF syndrome. This is because cardiomyocyte Ca2+-loading  is 
associated with enhanced myocardial oxygen (O2) consumption, increased heart rate (HR) and greater 
risk of arrhythmias contributing to the higher morbidity and mortality rates. 
 
1.6. Sarcomere targeted agents for the treatment of AHF 
Based on the deleterious side effects of the traditional inotropes, novel inotropic agents with different 
mechanism of action were required for the treatment of AHF. Theoretically, clinical use of sarcomere 
targeted drugs would avoid the disadvantages of Ca2+ mobilizers in the therapy of AHF syndrome. 
This is because pharmacological modification of the cardiac sarcomere is not expected to interfere 
with the intracellular Ca2+ homeostasis at all or not to the same degree. Several different terms and 
concepts have been associated with cardiac sarcomere targeted agents, i.e. 1.) Ca2+ sensitization of 
contractile filaments, 2.) direct cardiac myosin activation and 3.) drugs with added myofilamental 
effects (e.g. SR-33805 and HNO donors). Of note, sarcomere activating inotropes may exert 
pleiotropic cardiovascular effects, as direct activation of the cardiac sarcomere may be further 
supported by added non-myofilamental mechanisms (i.e. PDE III inhibition), evoking potentially 
additional hemodynamic and metabolic advantages or perhaps deleterious side effects. Minority of the 
sarcomere targeted agents possess only pure direct myofilamental effects, which makes them possible 
to evoke a clear cardiac selective mechanism of action. 
 
1.6.1. Potential usefulness of Ca2+ sensitizer drugs in AHF syndrome 
Ca2+ sensitization refers to increased contractile force production at a given [Ca2+]. In fact force 
augmentation can be achieved via different molecular mechanisms leading to various modifications in 
the [Ca2+] - contractile force relationship. Considering the interaction between Ca2+ and the cardiac 
troponin C (cTnC) as a reference point within the contractile activation process, inotropic 
interventions can be classified as those with (a) upstream mechanisms (increasing the amplitude of the 
intracellular Ca2+ transient), (b) central mechanisms (promoting the interaction between Ca2+ and 
cTnC; e.g. levosimendan) or (c) downstream mechanisms (directly modulating the actin – myosin 
interactions; e.g. by EMD-53998). The latter two actions are conventionally lumped together as Ca2+- 
sensitizing positive inotropy. 
Levosimendan interacts specifically with the hydrophobic region of cTnC close to its D/E 
linker domain on the N-terminal region, where the consequence of levosimendan binding is the 
stabilization of the open conformation of cTnC – Ca2+  complex strengthening its binding to cTnI. In 
other words, levosimendan increases the affinity of cTnC – Ca2+ complex for the cTnI and thus 
promoting a Ca2+ sensitizer effect via a disinhibition mechanism. Diastolic function is not impaired by 
levosimendan treatment, as drug binding to the N-terminal region of cTnC is highly Ca2+ dependent 
with a subsequent release from the binding site at diastolic Ca2+ levels. Levosimendan was reported to 
be highly selective enzyme inhibitors for the PDE III and especially at higher plasma concentration for 
the PDE IV isozymes in vitro. Preclinical data suggested that levosimendan can exert a positive 
inotropic effect via a Ca2+ sensitizing mechanism without modifications in the intracellular [Ca2+]. 
Levosimendan was also characterized as a potent cardio-protective drug, which is attributable directly 
to the vasodilation by opening adenosine triphosphate-dependent K+- channels (KATP) in the vascular 
smooth muscle and indirectly to the activation of similar KATP channels in the mitochondria. Despite 
of the positive messages of previous preclinical trials, novel clinical studies failed to confirm the 
superiority of levosimendan to the traditional inotropic agents. The initial optimism driven by the 
improvement of short and mid-tem mortality in early clinical trials (LIDO and RUSSLAN) was 
tempered by the less favorable outcomes of recent studies (SURVIVE and REVIVE). Nevertheless, 
more recent meta-analyses have reported that administration of levosimendan is associated with a 
significant reduction of mortality in critically-ill patients and in those of undergoing cardiac surgery. 
The chemical substitution of the structure of levosimendan resulted in the development of a 
novel levosimendan related chemical entity, ORM-3819, exerting its hypothesized positive inotropic 
effect via a cTnC-dependent Ca2+ sensitizing mechanism. ORM-3819 may have a different pattern of 
side effects than that of levosimendan evoked, which would represent a new therapeutic possibility for 
the treatment of AHF when levosimendan is contraindicated or well-tolerated. Common side effects of 
levosimendan are hypotension and headache due to its vasodilating properties occurring more 
frequently in case of application with high loading doses. Atrial fibrillation, hypokalaemia and 
tachycardia are considered as less common adverse events. This study is therefore a complete 
pharmacological characterization  of ORM-3819  regarding  its Ca2+ sensitizing mechanism, cTnC- 
binding capacity and other pleiotropic effects. 
 
1.6.2. Cardiac myosin activation represents a novel therapeutic approach for AHF 
Myosin activation represents potentially another mechanism of sarcomere targeting by increasing the 
ATPase rate of the cardiac myosin heads. Omecamtiv mecarbil (OM) previously referred as CK- 
1827452 exerts a positive inotropy via its selective binding to the S1 domain of the cardiac myosin 
where the relay helix and converter domain converge at the base of the force producing lever arm. The 
mechanism of action evokes a conformational change in the nucleotide binding domain of the cardiac 
myosin head contributing to the allosteric activation of its mechanical and enzymatic properties. 
Consistent with the allosteric modulation in the nucleotide binding domain of the cardiac myosin, 
omecamtiv mecarbil accelerates the inorganic phosphate release from the myosin heads, which is the 
rate limiting step of the acto-myosin cycle. In other words, OM increases the ATPase rate of the 
cardiac myosin, accelerating thereby the transition rate from the weakly to the strongly actin-bound 
conformation. This kind of mechanism of action also suggests that myosin activation may result in an 
increase of the available force-producing myosin heads in the sarcomere, indicating “more hands 
pulling on the rope”. Since application of OM is associated with increased myocardial contractility 
without any changes in the Ca2+ homeostasis, myosin activation might be regarded as a potential 
downstream Ca2+ sensitizing positive inotropy. 
In preclinical trials, OM significantly increased the contractility of isolated rat cardiomyocytes 
without any changes in the Ca2+ homeostasis measured by the fluorescent Ca2+ indicator. Furthermore, 
myosin activation resulted in an increase not only in the magnitude but also in the duration of 
contraction. 
In an in vivo dog model with pacing induced systolic HF after myocardial infarction or chronic 
pressure overload, OM infusion was shown to enhance the LV systolic performance without 
increasing the myocardial O2 consumption. Moreover, OM failed to affect the diastolic performance of 
the chambers. 
As the preclinical data demonstrated beneficial cardiovascular effects of myosin activation, 
OM was tested in clinical studies in order to determine the dose-dependent augmentation of the 
cardiac function, as well as the maximum tolerated doses and plasma concentration of the drug. In 
healthy human volunteers and patients with NYHA III-IV HF, OM was reported to enhance the 
systolic functions of the LV. Cardiac myosin activation was not accompanied by impairments in the 
diastolic functions, although the dose-limiting toxic effect was myocardial ischaemia due to the 
detailed prolongation of the systolic ejection time. Furthermore, OM was shown to evoke beneficial 
hemodynamic effects after oral administration, as well. Most recently, a randomized, controlled phase 
IIb trial (ATOMIC-AHF) was undertaken to evaluate the safety and efficiency of OM in those of 
hospitalized with AHF. The ATOMIC-AHF revealed that myosin activation did not meet the primary 
end-point of the study, as no significant effect on dyspnea was demonstrated. Nevertheless, 
administration of OM proved to be clinically safe and the results also suggested a tendency towards 
reduction of worsening HF. In the COSMIC-HF study, OM was administered for chronic HF patients 
and was confirmed effective similarly to that of previous studies. Despite the growing preclinical and 
clinical evidence for OM, there is less data for OM related to its long effects on the morbidity and 
mortality rates of HF. 
 
1.7. Potential usefulness of sarcomere targeted agents in other diseases 
Acute or chronic HF is also associated with the decreased contractility of the diaphragm. Similar 
findings were reported after long term mechanical ventilation, in patients with chronic obstructive 
pulmonary disease (COPD) and in neuromuscular diseases. Those reports have shown that decreased 
contractility is attributable to its decreased Ca2+ sensitivity of the contractile machinery. Previous 
studies   preclinical  studies   have  revealed  that   levosimendan  and  EMD-57033   improved  the 
contractility of the failing diaphragm through their Ca2+ sensitizing mechanisms. Clinical data also 
confirmed that levosimendan increased the contractility of the respiratory muscles in patients with 
COPD or after long term mechanical ventilation. Myosin activation also represents a potential 
therapeutic approach for the treatment of respiratory insufficiency, because the slow-skeletal muscle 
fibres co-express the same MHC isoform (MHC-β) than that of in the heart, resulting in an OM- 
evoked Ca2+ sensitization. 
 
2. Aims 
This study is a complete pharmacological characterization of the myosin activator OM, and the 
levosimendan-related novel chemical entity, ORM-3819. Our goal was to elucidate the potential 
mechanisms underlying the inotropic effects of the above agents. 
Therefore, we aimed: 
1. To demonstrate and quantify the effects of OM on the mechanical (ΔpCa50, nHill, Fmax, Factive, 
Fpassive) and kinetic (ktr, t1/2akt, trelax) contractile parameters of isolated and permeabilized 
cardiomyocytes. 
2. To report on the tissue selectivity of OM by repeating the above investigations on skeletal 
muscle preparations of the rat diaphragm 
3. To compare the OM-evoked mechanical and kinetic changes between skeletal muscle fibres 
with slow and fast intrinsic kinetics. 
4. To demonstrate the hypothesized Ca2+ sensitizing effect of ORM.3819 
5. To identify another pleiotropic mechanisms of action of ORM-3819 underlying its potential 
positive inotropic effect. 
 
3. Material and methods 
3.1. Chemicals and muscle specimens 
OM, previously referred to as CK-1827452, was purchased from AdooQ BioScience (Irvine, CA, 
USA), ORM-3819 was provided by Orion Pharma. Stock solutions with a final OM concentration of 
10 mM were prepared in dimethyl sulfoxide (DMSO) as solvent and stored at 4 οC. Appropriate 
volumes of the concentrated stock solutions were dissolved in activating and relaxing solutions to 
obtain test solutions containing OM in the concentration range between 3 nM and 10 µM. The final 
concentration of DMSO never exceeded 0.1%. DMSO itself did not modify the contractility of the 
myocyte-sized preparations. 
Investigations were carried out on male 8-15-week-old Wistar-Kyoto rats and guinea pigs, 
weighing 250-500 g (Toxi-Coop Toxicological Research Center, Dunakeszi, Hungary; n = 20). The 
animals were fed a standard chow and drank tap water ad libitum and were housed in groups of two to 
three per polycarbonate cages in a room controlled thermostatically at 20 ± 2 °C with a target relative 
humidity of 55 ± 15%. The animals were anaesthetized with an intraperitoneal injection of sodium 
pentobarbital (Release, Garbsen, Germany; 150 mg kg-1). The heart and the diaphragm were quickly 
excised and the LV was dissected in cold isolating solution (MgCl2: 1 mM, KCl: 100 mM, EGTA: 2 
mM, adenosine triphosphate (ATP): 4 mM, imidazole: 10 mM; pH 7.0). Diaphragm and LV tissue 
samples were then stored at -80 οC. All procedures employed in this work conformed strictly to 
Directive 2010/63/EU of the European Parliament and were approved by the Ethical Committee of the 
University of Debrecen (Ethical Statement number: 1/2013/DE MÁB). 
 
3.2. In vitro isometric contractile force measurements 
Contractile force measurements were performed on single, mechanically isolated 
cardiomyocytes and diaphragm muscle fibres, as described previously. Briefly, deep-frozen (-80 oC) 
LV and diaphragm tissue samples were mechanically disrupted in isolating solution using a tissue 
homogenizer at 4 C, and thereafter subjected to chemical permeabilization with 0.5% Triton X-100 
detergent for 5 min. The Triton X-100 eliminated all membrane structures, allowing characterization 
of the mechanical properties of single myocytes under standardized conditions with the avoidance of 
potential disturbing factors present in vivo. Isolated and permeabilized single cardiomyocytes or 
skeletal muscle fibres being kept in Ca2+-free relaxing solution were attached with silicone adhesive 
(DAP 100% all-purpose silicone sealant; Baltimore, MD, USA) to two stainless insect needles, 
connected to a very sensitive force transducer (SensoNor, Horten, Norway) and an electromagnetic 
motor (Aurora Scientific Inc., Aurora, Canada). After adjustment of the sarcomere length to 2.3 µm, 
the contractile machinery was activated by transferring the preparation from the relaxing to the 
activating solution (the same components apart from containing Ca2+-EGTA instead of EGTA). The 
compositions of the activating and relaxing solutions were calculated by using a previously reported 
approximation. [Ca2+] were indicated as pCa values calculated by -lg[Ca2+]. The pCa of the relaxing 
solution was 9.0, and that of the activating solution was pCa 4.75. 
The Ca2+-induced contractions of the preparations were recorded with a custom-built 
LABVIEW Data Acquisition (DAQ) platform and analysed with LabVIEW analyzing software (Myo; 
National Instruments, Austin, TX, USA) after transfer from a droplet of relaxing to a droplet of 
activating solution. When the Ca2+-activated force production reached its maximum level (Fmax), a 
quick release – restretch manoeuvre (20 ms) was applied in the activating solution. As a result of this 
intervention, force first dropped to zero and then started to re-develop allowing the determination of 
the total force (Ftotal). The Ca2+-independent passive force level (Fpassive) was approximated by 
shortening of the preparations to 80% of the original lengths in relaxing solution for 8 sec. The active 
isometric force (Factive) level was calculated as the difference between Ftotal and Fpassive. Force values 
were normalized for the cross-sectional area determined from the width and height of the myocytes, 
approximating their dimensions with elliptic geometry. Values indicating the force production of the 
myocyte-sized preparations at a given [Ca2+] (pCa 5.4 – 9.0) normalized to Fmax were fitted to a 
modified Hill equation in Origin 6.0 (Microcal Software, Northampton, MA. USA) or GraphPad 
Prism 5.02 (GraphPad Software, Inc., La Jolla, CA, USA): The pCa value for the half-maximum 
contraction indicated by Ca50 or pCa50 defines the Ca2+ sensitivity of force generation of the contractile 
machinery, while the steepness of the Ca2+ sensitivity curve describing the myofilamental co- 
operativity was also calculated and expressed as a coefficient (nHill). 
In addition to the mechanical parameters of the myocyte-sized preparations, the kinetic 
parameters of the contractions were also assessed. The rate of isometric force production was 
determined by fitting the phase of isometric force generation following the Ca2+-activation until the 
release – -restretch manoeuvre to a single exponential by means of LabView analysing software. The 
force re-development after the release – restretch manoeuvre was also fitted to a single exponential 
function in order to evaluate the rate constant of force re-development (ktr,max). The half-time of 
activation (t1/2 of activation) was determined by estimating the duration for half-maximum contraction 
after the preparations were placed in activating solution. The relaxation time (trelax) was evaluated from 
the time point of the preparation being placed in relaxing solution until the baseline force level was 
reached. 
Statistical significance was calculated by analysis of variance (ANOVA, repeated measures) 
followed by Dunnet’s two-tailed test and paired or unpaired Student t test. Values are given as means 
± S.E.M. Statistical significance was accepted when P < 0.05. Statistical analyses were carried out 
with GraphPad Prism software. 
 
3.3 Analysis of the MHC isoform composition of the rat LV and diaphragm. 
The MHC isoform composition of the rat diaphragm and LV was analysed by using sodium 
dodecylsulfate (SDS) polyacrylamide gel electrophoresis. Deep-frozen muscle samples were 
homogenized and then boiled in sample buffer for 2 min. The adjusted final protein concentration was 
0.25 mg  ml-1.  Separate upper  and  lower  buffers  were used.  The running conditions  were 70  V 
(constant voltage) for 24 h at 4 C. The gels were stained with Coomassie Blue. 
 
4. Results 
4.1. Pharmacological characterization of the positive inotropic effect of OM 
4.1.1. The effects of OM on the mechanical contractile properties of the isolated rat cardiomyocytes. 
The possibility of a Ca2+ sensitizing effect of OM was investigated in permeabilized LV myocyte- 
sized preparations. Isolated and permeabilized cardiomyocytes were firstly treated with OM-free test 
solutions containing saturating (pCa 4.75) and submaximal (pCa 6.1) [Ca2+] to determine the Ca2+- 
activated maximum and submaximal contractile force production. The submaximal [Ca2+] was chosen 
to achieve a contractile force of 10-15% related to the Fmax. Then, increasing concentrations of OM 
were administered at the submaximal [Ca2+] to determine the Factive and Fpassive of the cardiomyocytes. 
The OM-evoked increase in Factive at pCa 6.1 was significant in the OM concentration range 
between 0.1 µM and 3 µM. The concentration – response relationship of OM was bell-shaped, with 
the highest levels of Ca2+ sensitization between concentrations of 0.3 µM and 1 µM (Factive in OM-free 
medium = 2.74 ± 0.40 kN m-2 vs. 8.66 ± 1.32 kN m-2 and 8.71 ± 1.29 kN m-2 at 0.3 and 1 µM OM, 
respectively; P <0.001, n = 8 individual preparations), while no Ca2+-sensitizing effect of OM was 
apparently exerted at 10 µM OM. The concentration – response relationship was fitted to a sigmoid 
function in the OM concentration range between 3 nM and 1 µM resulting in an EC50 of 0.08 ± 0.01 
μM. 
ΔpCa50 was assessed based on the pCa – force relationship after exposing the myocyte-sized 
preparations to test solutions (pCa 4.75 – pCa 9.0) containing 0.1 µM and 1 µM concentration of OM. 
0.1 µM and 1 µM OM increased the Ca2+ sensitivity of force production suggested by a leftward shift 
on the pCa – force relationship. The force augmentation was pronounced in the presence of 1 µM OM 
at low – intermediate [Ca2+] levels (i.e. between pCa 9.0 and pCa 6.0) referring to Ca2+ sensitization at 
diastolic Ca2+ levels. However, decreases in Fmax together with force reductions at high – intermediate 
Ca2+ concentrations were also observed, when illustrating isometric force production in absolute terms. 
When the leftward shifts of the pCa – force relationships evoked by 0.1 µM and 1 µM OM are 
illustrated by their respective mean pCa50 values, OM increased the Ca2+ sensitivity of force 
production (pCa50 in the OM-free medium = 5.86 ± 0.02 vs. 5.97 ± 0.02 and 6.20 ± 0.03 at 0.1 and 1 
µM OM; P < 0.05 and P <0.001 vs. the control, respectively; n = 8 individual preparations). 0.1 and 1 
µM OM decreased the nHill values of the pCa – force relationships (nHill  in OM-free medium = 2.56 ± 
0.07 vs. 1.66 ± 0.06 and 0.96 ± 0.05 at 0.1 and 1 µM OM; P <0.001 in both groups vs. the control, 
respectively). 
Thereafter, we investigated the OM-dependent decrease of Fmax  and the Ca2+  sensitization at 
diastolic Ca2+ levels in the presence of wide OM concentration range (10 nM - 10 µM). OM decreased 
Fmax in a monotonous fashion, the decreases proving significant at 1 µM OM concentration or higher 
(Fmax in OM-free medium = 14.75 ± 0.70 kN m-2 and at 1 µM OM concentration = 9.42 ± 0.97 kN m-2, 
P <0.001 vs. the control; n = 8). 
Ca2+ sensitization at diastolic Ca2+ levels was determined in relaxing solutions (pCa 9.0). OM 
increased the contractile force production between concentrations of 0.3 µM and 1 µM (Factive in OM- 
free medium ~ 0 kN m-2 vs. 1.77 ± 0.18 kN m-2 at 0.3 and 1 µM OM, respectively; P < 0.01; n = 6) 
similarly to that of observed at submaximal [Ca2+]. 
OM increased Fpassive at 0.3 µM and higher (Fpassive in OM-free medium = 1.2 ± 0.12 kN m-2 
and at 0.3 µM OM = 2.29 ± 0.31 kN m-2; P < 0.001 vs. the control; EC50 = 0.31 ± 0.1 µM; n = 8). 
 
4.1.2. Effects of OM on the kinetics of activation–relaxation cycles in isolated rat cardiomyocytes   
To obtain  a  more  detailed  picture  as  concerns  how OM  affects  the  kinetics  of  Ca2+-dependent 
activations and relaxations, contractile force measurements were carried out at saturating (pCa 4.75) 
and submaximal (pCa 6.0) [Ca2+] in a wide range of OM concentrations (between 3 nM and 10 µM). 
At pCa 4.75, OM decreased ktr at 10 nM and higher concentration (ktr in OM-free medium: 
5.70 ± 0.33 s−1 and 4.44 ± 0.37 s−1 at 10 nM OM; P <0.01 vs. the control; EC50: 0.05 ± 0.01 μM; n = 
8). Interestingly, OM-dependent  changes  of ktr were biphasic at pCa 6.0, as ktr increased in the 
presence of 0.1 μM OM from the drug-free control of 1.31 ± 0.08 s−1 to 1.57 ± 0.08 s−1 (P < 0.05 vs. 
the control), albeit ktr decreased in the presence of 0.3 μM and higher OM concentrations (to 1.00 ± 
0.11 s−1 at 0.3 μM OM; P <0.01 vs. the control; n = 8). 
OM treatment resulted in the prolongation of duration of contractile force production. 1 μM 
and higher concentrations of OM increased significantly the t1/2 of activation at pCa 4.75 (t1/2 in OM- 
free conditions: 0.77 ± 0.12 s and 4.02 ± 0.56 s at 1 μM OM, P <0.001 vs. the control) and at pCa 6.0 
(t1/2 in OM-free conditions: 2.55 ± 0.19 s and 4.23 ± 0.53 s at 1 μM OM, P <0.05 vs. the control; n = 
8). 
Similar kinetic features were observed on the relaxation of the preparations. The relaxation 
was slowed following Ca2+- removal from the preparations at 1 μM and higher OM concentrations at 
pCa 4.75 (trelax in the OM-free medium: 1.19 ± 0.10 s and 3.75 ± 0.31 s at 1 μM OM; P <0.001 vs. 
control) and at pCa 6.0 (trelax in the OM-free medium: 0.61 ± 0.06 s and 4.36 ± 0.77 s at 1 μM OM; P 
<0.001 vs. control; n = 8). 
 
4.2. The effect of OM in isolated muscle fibres of rat diaphragm 
A complicating factor in diaphragm muscle preparations is the composition of muscle fibres with 
different MHC isoforms. A mixture of abundant proteins with distinct molecular weights close to 
those of MHC was visualized during the SDS-PAGE of the rat diaphragm, reflecting skeletal muscle 
fibres of types I(β), IIx, IIb and IIa. Importantly, MHC isoform type I co-migrated with the α+β 
isoforms of the LV samples, indicating similar molecular weights and hence suggesting similar 
structures for these MHC isoforms. Although we could not extend the mechanical measurements on 
isolated muscle fibres to biochemical MHC isoform subtyping, the ktr,max parameters (measured at pCa 
4.75) allowed the differentiation between muscle fibres with slow (ktr,max < 2 s-1) and fast kinetics 
(ktr,max =  2-7  s-1), most probably reflecting isoform compositions  of type I(β) vs. type II fibres, 
respectively in the investigated preparations. 
 
4.2.1. OM-dependent changes in the mechanical contractile parameters of isolated muscle fibres of 
rat diaphragm with slow intrinsic kinetics 
The effect of OM the mechanical contractile parameters of isolated skeletal muscle fibres with slow 
endogenous kinetics (ktr,max = 1.61 ± 0.22 s-1) was assessed similarly  to  that of investigated  in 
cardiomyocytes. OM increased the Factive  at pCa 6.0 significantly in the concentration range between 
0.1 µM and 3 µM. The OM-dependent Ca2+  sensitization was characterized by an apparent EC50  of 
0.48 ± 0.07 µM (n = 14 isolated myofibers). 
The Ca2+-sensitizing effect of OM was also demonstrated by comparing pCa – force 
relationships in diaphragm muscle preparations with low ktr,max (1.50 ± 0.10 s-1) following exposure to 
1 µM OM. OM increased the Ca2+ sensitivity of force production in the isolated rat diaphragm muscle 
fibres (pCa50 in OM-free controls = 5.61 ± 0.02 and at 1 µM OM = 5.85 ± 0.03; P <0.001; n = 9). This 
OM concentration exerted less effect on the force production at either the highest or the lowest applied 
[Ca2+] than those in the isolated cardiomyocytes. 
Although 1 µM OM had no effect on Fmax previously, we investigated its hypothesized effects 
in the presence of wide concentration range (10 nM - 10 µM). 3 µM and higher OM decreased Fmax 
significantly in muscle fibres with low ktr,max (Fmax in OM-free medium = 21.37 ± 3.16 kN m-2 and at 3 
µM OM = 13.26 ± 1.78 kN m-2; P <0.001; vs. the control; n = 6). 
Fpassive of the slow skeletal fibre preparations were significantly increased at 1 µM and higher 
OM concentrations (Fpassive in OM-free medium = 1.2 ± 0.15 kN m-2 and at 1 µM OM = 1.75 ± 0.42 kN 
m-2; P <0.01 vs.the control; EC50 = 0.79 ± 0.16 µM; n = 6). 
 
4.2.2. The effect of OM on the kinetic contractile parameters of the isolated muscle fibres with slow 
intrinsic kinetics 
OM decreased ktr, both at pCa 4.75 and 6.0, however OM was more potent at pCa 4.75 (EC50 = 
0.13 ± 0.09 µM) than that of at pCa 6.0 (EC50 = 0.29 ± 0.04 µM) 
The kinetic features of the OM effects were also reflected by increased t1/2 of activation and 
trelax in diaphragm myofibres with low ktr,max. OM significantly increased the t1/2 of activation at 1 µM 
and higher concentration either at pCa 4.75 (t1/2 of activation in OM-free medium: 5.99 ± 0.98 s and at 
1 µM OM: 13.98 ± 1.46 s, P <0.001 vs. the control) or at pCa 6.0 (t1/2 of activation in OM-free 
medium: 6.96 ± 0.86 s and at 1 µM OM: 10.50 ± 0.93 s, P <0.001 vs. the control). 0.3 µM and higher 
OM slowed the relaxation at pCa 4.75 (trelax in OM-free medium: 3.15 ± 0.68 s and at 0.3 µM OM: 
5.49 ± 0.81 s; P <0.05 vs. the control), while proving significant at 1 µM OM and higher at pCa 6.0 
(trelax in OM-free medium: 0.86 ± 0.09 s and at 1 µM OM: 7.26 ± 0.83 s; P <0.01 vs. the control; n = 
11-14) 
 
4.2.3. Mechanical and kinetic effect of OM for the isolated muscle fibres with fast intrinsic kinetics 
OM exhibited a significant Ca2+-sensitizing effect at 1 µM concentration and higher at pCa 5.8 (Factive 
in OM-free medium: 4.59 ± 0.99 kN m-2 and 6.97 ± 1.30 kN m-2 at 1 µM OM; P <0.05 vs. the control) 
in fast skeletal muscle preparations (ktr;max: 4.40 ± 0.29 s-1). OM-dependent changes in the Factive  were 
less when compared to that of evoked in cardiomyocytes and slow skeletal muscle preparations. Fmax 
of the preparations was not affected by OM. 
OM treatment did not increase the Fpassive of the myocyte-sized preparations either at pCa 4.75 
or at pCa 5.8. 
OM decreased the ktr at 1 µM concentration and higher at pCa 4.75 (EC50: 1.23 ± 0.28 µM), 
however the decrease of the ktr was abolished at pCa 5.8. 
OM effect was associated with faster Ca2+-contractions at pCa 5.8 (t1/2 of activation in OM- 
free medium: 8.73 ± 0.70 s and at 1 µM OM: 4.92 ± 0.97 s, P <0.05 vs. the control), whereas the 
relaxation of the preparations was not affected following Ca2+ removal. Investigations were performed 
at 6 - 6 isolated and permeabilized myofibers. 
 
4.3. Ca2+-sensitizing effects of ORM-3819 in isolated and permeabilized cardiomyocytes 
After characterizing the pharmacological effect of OM, we have focused on the hypothesized positive 
inotropic effect of the novel levosimendan-related chemical entity, ORM-3819. Isolated and 
permeabilized cardiomyocytes from guinea pig LV were treated at a submaximal [Ca2+] (pCa 5.8) with 
increasing concentrations of ORM-3819 while registering the Factive and Fpassive of the myocyte-sized 
preparations. The ORM-3819-evoked  increase in Factive was  significant at 3  µM and  higher OM 
concentration. (Factive in ORM-3819-free medium: 3.38 ± 0.32 kN/m2 kN m-2 vs. 4.77 ± 0.4 kN m-2 at 3 
µM ORM-3819, respectively; P <0.05; n = 10) and its Ca2+-sensitizing effect was characterized by a 
half-maximal concentration (EC50) of 2.88 ± 0.14 µM. 
To obtain more details on the Ca2+-sensitizing effect of ORM-3819, isometric force production 
was also assessed at maximal (pCa 4.75) and submaximal [Ca2+] (i.e. between pCa 5.4 – pCa 7.0) in 
the absence and in the presence ORM-3819, respectively. 10 µM, 30 µM and 100 µM ORM-3819 
exerted comparable Ca2+-sensitizing effects, and therefore 10 µM test concentration of ORM-3819 
was used to determine the drug evoked changes on the pCa – isometric force relations. Accordingly, 
ORM-3819 treatment resulted in a leftward shift on the pCa – isometric force relationship, when 
compared to that of untreated cardiomyocytes (n = 10 – 10 cardiomyocytes). ORM-3819 did affect the 
isometric force production neither at the maximal (i.e. pCa 4.75) nor at the lowest (i.e. pCa 7.0) 
applied [Ca2+]. The [Ca2+] required to evoke half of the maximal force production (i.e pCa50) reflected 
the change in Ca2+ sensitivity of force production: i.e. it was pCa 5.69 ± 0.01 in the absence and pCa 
5.81 ± 0.01 in the presence of 10 µM ORM-3819 (ΔpCa: 0.12 ± 0.01; P <0.001; n = 10). ORM-3819 
did not affect the Ca2+-independent Fpassive production at any applied concentration. 
Thereafter, the ORM-3819-dependent changes in the activation-relaxation cycles were 
investigated similarly to that of carried out to assess the OM-evoked kinetic effects. Cardiomyocytes 
were exposed to increasing concentrations of ORM-3819 in a wide concentration range (0.3 µM – 10 
µM), while assessing the drug-induced changes of the ktr, t1/2 of activation and trelax. Previously, 10 µM 
had no effect on Fmax and Fpassive, therefore investigations were not repeated at pCa 4.75. ORM-3819 
increased the ktr at submaximal [Ca2+] (pCa 5.8) at 10 µM and higher concentrations (ktr in ORM- 
3819-free medium: 0.30 ± 0.05 s−1  and 0.49 ± 0.04 s−1  at 10 µM ORM-3819, P <0.05; EC50: 5.34 ± 
0.45 μM; n = 10). ORM-3819 seemed to accelerate the contraction of the myocyte-sized preparation, 
but the evoked changes failed to prove significance. ORM-3819 had no effect on the relaxation of the 
preparations. 
 
5. Discussion 
This study is a pharmacological characterization of the positive inotropic effect of the myosin activator 
OM and the levosimendan-related ORM-3819 regarding those of mechanical and kinetic effects on the 
contractility of the myocyte-sized preparations.OM was demonstrated to increase the Ca2+ sensitivity, 
and Fpassive, slowed the kinetics the activation – relaxation cycles of the rat cardiomyocytes while 
increasing force production at very low [Ca2+] comparable to that of diastolic levels. OM-evoked 
changes in the mechanical and kinetic contractile properties were less in skeletal muscle fibres with 
slow intrinsic kinetics and even lesser in those with fast intrinsic kinetics than that of exerted in 
cardiomyocytes. ORM-3819 evoked a cTnC-dependent Ca2+ sensitizing effect with totally different 
kinetics when compared to that of OM exerted. 
This study is the first quantitation of the Ca2+ sensitizing effect of the novel myosin activator 
OM in isolated and skinned cardiomyocytes. Previous studies reported on the OM-evoked changes in 
the Ca2+ sensitivity of myosin ATPase activity, although similar relationship for the OM-evoked 
changes in the Ca2+-dependence of the contractile force production was previously not demonstrated. 
Hereby, 0.1 µM and 1 µM OM increased the Ca2+ sensitivity of force production suggested by a 
leftward shift on the pCa – force relationship. Considering the interaction between Ca2+ and the cTnC 
as a reference point within the contractile activation process, Ca2+ sensitization can be classified as 
those with central and downstream mechanism of action. This suggests that myosin activation can be 
regarded actually as a downstream Ca2+-sensitizing mechanism interfering with the actin – myosin 
interaction. Ca2+ sensitizers may affect myocardial force production at a wide [Ca2+] range. 
Nevertheless, it is hard to estimate, how much is the physiological systolic and diastolic intracellular 
[Ca2+] because those of the continuous fluctuation by Ca2+ channels and pumps of the cell membrane 
and SR. Hence, the systolic [Ca2+] may be approximated as 1 μM concentration (pCa 6.0), which 
decreases to 10 nM during diastole. Ca2+ sensitizers acting on the central pathway of positive inotropy 
(i.e. levosimendan) may increase force production especially at systolic Ca2+ levels, while those of 
affecting the cross-bridge cycling of the myofilaments may alter force production at systolic and 
diastolic [Ca2+], as well. EMD-53998, a known downstream Ca2+ sensitizer binding to the myosin 
motor at the base of the lever arm located close to the proposed binding site of OM, increased the 
contractility of the myocyte-sized preparations at pCa 9.0 and pCa 4.75. OM also exerted robust Ca2+ 
sensitizing effects through a wide range of [Ca2+], but both the extent and the direction of the evoked 
changes (force enhancement vs. force mitigation) depended on the applied OM concentration. 0.1 µM 
OM increased the isometric force production mainly at systolic [Ca2+], while at 1 µM OM, contractile 
force development was also observed at very low [Ca2+] (pCa 7.0 – 9.0), as suggested by the upward 
shift in the pCa – force relationships. Furthermore, the Ca2+  sensitizing effect of OM was absent at 
pCa 4.75, suggesting that the available number of strongly-bound cross-bridges are maximal under 
this condition. Moreover, Fmax rather tended to decline at high OM concentrations due to the excessive 
cross-bridge activation consistently with the abolished Ca2+ sensitization at submaximum [Ca2+] in 
response of high OM concentrations. Our present data corroborate a similar relationship for the OM- 
evoked changes in the Ca2+-dependence of the myosin ATPase activity suggested by previous studies. 
Accordingly, Malik at al. found increased ATPase rate at [Ca2+] lesser than that of pCa 7.0 related to 
the isometric force increase at diastolic Ca2+ levels, resulting potentially in diastolic dysfunction. 
Additionally, OM was also demonstrated to inhibit the actin – myosin complex dissociation rate 
following Pi release while our results reported on increased Fpassive and relaxation time of the 
cardiomyocytes. The increased Ca2+ sensitivity of force production has been observed in advanced 
stages of HF. Moreover, Ca2+ sensitization at diastolic [Ca2+] may be complicated by an already 
elevated cytosolic [Ca2+] during diastole in HF. All of the above components may complicate 
ventricular relaxation during OM treatment especially at high doses. Accordingly, increases in the 
time constant of isovolumic relaxation (τ) and the rate of the LV pressure decrease (dP/dtmin) reflected 
impaired diastolic performance after intravenous OM administration in rats with volume overload HF. 
Despite of the in vitro mechanical and kinetic effects, OM treatment did not compromise the diastolic 
functions in healthy volunteers or in patients with systolic HF at plasma concentrations similar to 
those applied in this study (400 – 600 mg ml-1/0.5 – 3 µM). It must therefore be acknowledged that 
extrapolation from in vitro data to in vivo conditions can be complicated by the distinct interactions of 
OM with the actin – myosin system in permeabilized preparations and in the structurally intact 
myocardium. Through the use of an isolated single-cell experimental arrangement, the contractile 
machinery was directly exposed to OM, in contrast with the structurally intact fibres, and hence 
resulting in a potentially greater extent of myosin activation at the applied concentration range than 
that achieved in vivo. Furthermore, the intracellular concentration of OM remained unknown, even 
complicated by its binding to the plasma proteins (82%). 
Previous studies suggested that the increased ATPase rate is the major determinant for 
cardiotonic effect of OM. Nevertheless, more recent data showed decreased rate of the steady-state 
ATPase activity in response to OM, while myosin activation was only associated with increased ATP 
hydrolysis and Pi release rates. Acceleration of the Pi release rate is in contrast to the slowed cross- 
bridge cycling manifesting in increased duration of contraction, which is mainly attributable to OM- 
evoked decrease in the rate of the actin – myosin cycling. Anyhow, it is widely accepted that the 
increased Pi release and unchanged ADP dissociation by OM results in increased available number of 
cross-bridges during cardiac contractions without affecting the intracellular Ca2+ homeostasis. 
Recruiting of strongly-bound cross-bridges by OM may delay the inactivation of the thin filaments as 
Ca2+ level fall and hence resulting in their sustained activation paralleled by increased force 
generation. Increased number of strongly-attached cross-bridges may therefore lead to the prolonged 
activation of the contractile machinery. Hence, our kinetic data of increased t1/2  of activation and 
decreased ktr corroborate the slowed in vitro motility of the myosin filaments and decreased 
contraction and relaxation velocity of the cardiomyocytes, potentially manifesting in increased systolic 
ejection time. Additionally, sustained thin filament activation may delay the kinetics of the force 
decay. Furthermore, OM decreased the ATP-initiated dissociation rate of acto-myosin. Together these 
changes may impair the relaxation of the myocardium, further supported by our results of increased 
trelax. Hence, OM treatment may result in stronger, slower and prolonged cardiac contractions 
consistently with echocardiographic results. These results may indicate that in  therapeutic 
concentration range, OM does not necessarily act as a myosin ATPase activator but rather is an 
allosteric modulator on the myosin motor. 
Our study firstly demonstrated that OM increased the contractility of the isolated and 
permeabilized skeletal muscle fibres of the rat diaphragm. A complicating factor in diaphragm muscle 
preparations is the composition of muscle fibres with different slow [types I (β)] and fast (type IIa, IIx 
and IIb) MHC isoforms. Although we could not extend the mechanical measurements on isolated 
muscle fibres to biochemical MHC isoform subtyping, the ktr,max parameters allowed the differentiation 
between muscle fibres with slow (ktr,max < 2 s-1) and fast kinetics (ktr,max = 2-7 s-1), most probably 
reflecting isoform compositions of type I (β) vs. type II fibres, respectively in the investigated 
preparations. In the present study, OM exerted its Ca2+  sensitizing effect in the slow skeletal muscle 
fibres of the rat diaphragm because of co-expressing the same MHC isoform (MHC-β) than that of in 
the heart. Our present data additionally demonstrated that OM exerted its effect on the Ca2+ sensitivity 
of force production and on the kinetic characteristics of the slow diaphragm preparations at a higher 
concentration range than in isolated cardiomyocytes due to their different thin filament composition. 
Moreover, our data probably suggest that OM may influence the contractility of the muscle fibres with 
fast-skeletal MHCs, although its Ca2+ sensitizing potency was even lower in isolated muscle fibres 
with high ktr,max than in those developing low ktr,max, with less effects on Fpassive production and the 
kinetics of activation – relaxation cycling. HF is also associated with the decreased contractility of the 
diaphragm attributable  to its decreased Ca2+ sensitivity. Further, mechanical ventilation is 
accompanied by the impaired contractile performance of the respiratory muscles. Previous studies 
have revealed that levosimendan and EMD-57033 improved the contractility of the failing diaphragm 
through their Ca2+ sensitizing mechanisms. In the present study, OM exerted its Ca2+ sensitizing effect 
in the skeletal muscle fibres of the rat diaphragm. As reported on the ATOMIC-HF trial, the treatment 
of HF patients with OM may decrease the incidence of dyspnoea. Our present study suggests that this 
might be due in part to the enhanced contractility of the diaphragm resulting particularly from Ca2+ 
sensitization. 
Our study also characterized the mechanism action of ORM-3819 related to its hypothesized 
positive inotropic effect. Due to structural similarities to that of levosimendan, ORM-3819 was also 
suggested to evoke a cTnC-dependent Ca2+ sensitization. NMR results clearly confirmed that similarly 
to that of levosimendan, ORM-3819 binds to the N-terminal domain of cTnC, however the binding 
site of ORM-3819 to cTnC could not be located. After demonstrating the binding of ORM-3819 to the 
cTnC, the hypothesized Ca2+ sensitizing effect was investigated on isolated and permeabilized 
cardiomyocytes derived from guinea pigs LV in response to ORM-3819 application. Although the 
magnitude of the Ca2+ sensitizing potency of ORM-3819 was comparable to that of levosimendan 
(ΔpCa50: ~ 0.1 pCa unit for levosimendan vs. ~ 0.11 pCa unit for ORM-3819), ORM-3819 exerted its 
Ca2+ sensitizing effect at higher drug concentrations than that of levosimendan (ECa50: ~ 9 nM for 
levosimendan vs. ~ 3 µM for ORM-3819) Therefore, it is to be acknowledged, that although ORM- 
3819 may sensitize the contractile protein machinery for the activating Ca2+  via binding to cTnC, the 
higher EC50 for the Ca2+ sensitizing effect points to a relatively small affinity of ORM-3819 for cTnC- 
binding, when compared to that for levosimendan. Similar differences of concentration-dependence 
was observed, when the in vitro and ex vivo positive inotropic effect was compared. The 
concentration-dependence for the Ca2+-sensitizing effect of ORM-3819 in isolated cardiomyocytes 
clearly did not overlap that obtained in Langendorff-perfused working heart preparations, where the 
concentration – response relationship for the positive inotropic effect of ORM-3819 was positioned 
leftward from that of Ca2+ sensitization. Therefore, our collaborating partners showed that ORM-3819 
application progressively decreased the activity both of the PDE III and PDE IV isozymes. Of note, 
ORM-3819 appeared to be a more potent inhibitor of PDE III when compared to that of PDE IV. 
Structure-to-activity investigations revealed that the pyridazinone ring, also present in ORM- 3819 is a 
critical determinant for PDE III inhibition with the nitrogen preferably unsubstituted, which interacts 
directly with the catalytic domain of the PDE III isozyme. These data suggest, that ORM-3819 may 
possess a dual mechanism of action, at low ORM-3819 concentrations PDE III inhibition could be 
dominantly involved in its positive inotropic effect, while at higher ORM-3819 concentrations Ca2+ 
sensitization could also contribute. This dual mechanism of action of ORM-3819 is in contrast to that 
for levosimendan, which acts mainly on TnC-dependent Ca2+ sensitization to exert its positive 
inotropic effect in its therapeutic concentration range. It is to be pointed out that the PDE inhibitory 
effect of ORM-3819 was highly selective for PDE III. This is not the case with most other known PDE 
III inhibitors (i.e. enoximone and milrinone), where the selectivity ratio for PDE III vs. PDE IV 
inhibition is significantly lower than that for ORM-3819. The above factors may contribute to avoid 
the deleterious side effects of the Ca2+ mobilizers in case of ORM-3819 administration. Indeed, the 
pleiotropic effects of ORM-3819  and  other less pure Ca2+-sensitizing agents  (i.e. levosimendan) 
represent a fascinating approach for the treatment of HF while avoiding the potential drawbacks of 
pure Ca2+-sensitizers and PDE inhibitors. As potential limitations of our study, the in vivo PDE III 
inhibitory effect of ORM-3819 had to be addressed based on in vitro measurements in response to 
ORM-3819 application without determining the changes of the intracellular cAMP and 
phosphorylation level. Furthermore, concerning the anti-stunning effect of levosimendan, the potential 
effect of ORM-3819 on the opening of ATP-dependent potassium channels was not investigated in this 
study. 
 6. Summary 
While Ca2+-mobilizer positive inotropic agents are nowadays less favored in acute heart failure, direct 
activation of the cardiac sarcomere became an attractive strategy for the treatment of acute 
decompensation. The Ca2+-sensitizer levosimendan is now widely accepted to give inotropic support 
for the failing heart and cardiac myosin activation by omecamtiv mecarbil (OM) is also increasingly 
considered as a future therapeutic agent in heart failure. 
Our aim was to assess the mechanical and kinetic effects of OM and the levosimendan-related 
ORM-3819 on the contractile function of isolated and permeabilized cardiomyocytes. In addition, we 
also aimed at the clarification of the tissue selectivity of OM during contractile force measurements in 
skeletal muscle myofiber preparations from the diaphragm. At a given submaximal [Ca2+] OM 
increased the Ca2+-sensitivity of force production  in  cardiomyocytes  in the presence of low and 
intermediate OM concentrations, but high OM concentrations did not augment force production. OM 
dependent Ca2+-sensitization was also observed at very low [Ca2+] levels mimicking diastolic 
conditions, and it also increased Fpassive. OM decreased the rate of the actin-myosin cross-bridge cycle. 
Due to the above mechanic and kinetic effects, OM treatment led to strong, slow and long-lasting 
Ca2+-contractures. OM evoked similar effects in skeletal muscle fibers with slow intrinsic kinetics, 
nevertheless, OM possessed lower affinity for skeletal muscle fibers than for cardiomyocytes. In fast 
skeletal muscle preparations, OM-evoked mechanical changes were observed only at high OM 
concentrations. The levosimendan-related  ORM-3819 also  increased  the Ca2+-sensitivity of force 
production of the cardiomyocytes, however with a different mechanism of action than OM. ORM- 
3819-evoked Ca2+-sensitization was accompanied by strong Ca2+-contractures due to increased rates of 
cross-bridge cycling. ORM-3819 failed to evoke Ca2+-sensitization at very low [Ca2+] and it did not 
increase Fpassive. 
Our data demonstrated OM as a Ca2+-sensitizing agent with a downstream mechanism of 
action in both cardiomyocytes and diaphragmatic muscle fibers. We propose that OM should be 
administered with care in patients with heart failure because of its potential adverse effects on 
myocardial relaxation. ORM-3819 was characterized as a cTnC-dependent Ca2+-sensitizer, thereby 
acting centrally in the contractile process. The positive inotropic effect of ORM-3819 is 
complemented by its selective inhibition of PDE III isoenzymes. 
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